Effects of proton pump inhibitors on inflammatory bowel disease: An updated review

被引:3
作者
Liang, Yu [1 ]
Meng, Zhen [2 ]
Ding, Xue-Li [3 ]
Jiang, Man [1 ]
机构
[1] Qingdao Univ, Dept Pharm, Affiliated Hosp, 16 Jiangsu Rd, Qingdao 266003, Shandong, Peoples R China
[2] Qingdao Univ, Dept Intervent, Affiliated Hosp, Qingdao 266003, Shandong, Peoples R China
[3] Qingdao Univ, Dept Gastroenterol, Affiliated Hosp, Qingdao 266003, Shandong, Peoples R China
关键词
Drug safety; Proton pump inhibitor; Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; FECAL CALPROTECTIN; RISK; ILAPRAZOLE; MECHANISM; ADULTS; DIAGNOSIS; OUTCOMES;
D O I
10.3748/wjg.v30.i21.2751
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Inflammatory bowel disease (IBD) is believed to be caused by various factors, including abnormalities in disease susceptibility genes, environmental factors, immune factors, and intestinal bacteria. Proton pump inhibitors (PPIs) are the primary drugs used to treat acid-related diseases. They are also commonly prescribed to patients with IBD. Recent studies have suggested a potential association between the use of certain medications, such as PPIs, and the occurrence and progression of IBD. In this review, we summarize the potential impact of PPIs on IBD and analyze the underlying mechanisms. Our findings may provide insights for conducting further investigations into the effects of PPIs on IBD and serve as an important reminder for physicians to exercise caution when prescribing PPIs to patients with IBD.
引用
收藏
页码:2751 / 2762
页数:13
相关论文
共 93 条
  • [1] Aberra F, 2006, GASTROENTEROLOGY, V130, pA649
  • [2] Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study
    Abrahami, Devin
    Pradhan, Richeek
    Yin, Hui
    Yanofsky, Russell
    McDonald, Emily Gibson
    Bitton, Alain
    Azoulay, Laurent
    [J]. GUT, 2023, 72 (07) : 1288 - 1295
  • [3] Proton pump inhibitors and risk of gastric cancer: population-based cohort study
    Abrahami, Devin
    McDonald, Emily Gibson
    Schnitzer, Mireille E.
    Barkun, Alan N.
    Suissa, Samy
    Azoulay, Laurent
    [J]. GUT, 2022, 71 (01) : 16 - 24
  • [4] Proton pump inhibitors and risk of colorectal cancer
    Abrahami, Devin
    McDonald, Emily Gibson
    Schnitzer, Mireille E.
    Barkun, Alan N.
    Suissa, Samy
    Azoulay, Laurent
    [J]. GUT, 2022, 71 (01) : 111 - 118
  • [5] Ahmed A, 2024, StatPearls Internet.
  • [6] Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander?
    Allin, Kristine Hojgaard
    Moayyedi, Paul
    [J]. GASTROENTEROLOGY, 2021, 161 (06) : 1789 - 1791
  • [7] Novel therapeutic targets for inflammatory bowel disease
    Argollo, Marjorie
    Fiorino, Gionata
    Hindryckx, Pieter
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. JOURNAL OF AUTOIMMUNITY, 2017, 85 : 103 - 116
  • [8] Cell Biology of Tight Junction Barrier Regulation and Mucosal Disease
    Buckley, Aaron
    Turner, Jerrold R.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2018, 10 (01):
  • [9] Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation
    Cader, M. Zaeem
    Kaser, Arthur
    [J]. GUT, 2013, 62 (11) : 1653 - 1664
  • [10] The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
    Cammarota, Giovanni
    Ianiro, Gianluca
    Cianci, Rossella
    Sibbo, Stefano
    Gasbarrini, Antonio
    Curro, Diego
    [J]. PHARMACOLOGY & THERAPEUTICS, 2015, 149 : 191 - 212